Researchers have made more advancements in multiple sclerosis in the last five years than in the previous 70 years. Knowing ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

ECTRIMS and EBMT said stem cell transplant can be considered for some with RRMS, such as those who are younger and have less severe disease.

The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...

The FDA reported that six patients died after being injected with Teva’s Copaxone or Sandoz’s Glatopa. The US Food and Drug ...

This 2022 paper indicates that prevention strategies for multiple sclerosis involve not smoking and treating vitamin D deficiencies. According to the MS Society, certain medications like ...

Mikael Simons, MD, a neurologist and researcher at Technical University Munich and the Centre for Neurodegenerative Diseases ...

From 1996-2024, 82 cases of anaphylaxis associated with glatiramer acetate were reported to the FDA Adverse Event Reporting ...

The FDA is adding a new boxed warning to include information that anaphylaxis can occur at any time, from as early as after ...

The drugs have demonstrated a 34% drop in the ... or take months or years after treatment initiation. A multiple sclerosis patient from Castlebar in Ireland died shortly after administering ...